ERBB2 and neoplasm: Compared to previous generations of HER2-targeted therapies, T-DXd offers enhanced potency, improved tumor penetration and reduced off-target toxicity (Nakada et al., 2019), which might have led to the observed good therapeutic outcomes of our patient, thereby addressing one of the major challenges of traditional therapies-overcoming tumor heterogeneity.